Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

19.60 +1.16 (+6.29%)
Streaming Delayed Price Updated: 3:57 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Why Zai Lab (ZLAB) Stock Is Trading Higher ↗
Zai Lab shares are trading higher by 4% during Friday's session. The company priced a $200 million public offering. 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conference in January 2025
From Zai Lab Limited
Via Business Wire
News headline image
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? ↗
Via The Motley Fool
News headline image
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
News headline image
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Zai Lab
Via Business Wire
News headline image
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
From Zai Lab
Via Business Wire
News headline image
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
From Zai Lab Limited
Via Business Wire
News headline image
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Proposed Public Offering of American Depositary Shares
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results ↗
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells. 
Via Investor's Business Daily
News headline image
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in November and December Investor Conferences
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
From Zai Lab Limited
Via Business Wire
News headline image
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.